Portage Biotech and Compedica Stock-for-Stock Exchange
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2025
0mins
Should l Buy ?
Source: Newsfilter
Portage Biotech and Compedica Agreement: Portage Biotech has entered a Subscription Agreement with Compedica, issuing 625,000 shares valued at $5 million in exchange for shares of Compedica, giving Compedica a 27.4% stake in Portage. The agreement includes a commitment for Portage to invest in Compedica's equity in future funding rounds.
Focus on Diabetic Foot Ulcers: Compedica aims to commercialize its OptiPulse medical device for treating diabetic foot ulcers, a significant health issue affecting millions globally. The company plans to publish clinical trial results by Q4 2025 and expects to launch the device commercially in North America in early 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
